The Indian Metabolic Disorders Therapeutics market size stood at around USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of 8.5% during the forecast period.
The metabolic disorder is increasingly common in India. The prevalence of metabolic syndrome (MetS) in Asian Indians varies according to the region, the extent of urbanization, lifestyle patterns, and socioeconomic/cultural factors. The one-third of Indians living in cities suffer from MetS with rates among females (range: 2.6%–65.9%) higher than those found in males (range: 8.4%–39.9%). The overall prevalence of metabolic syndrome was 1.5% among women and 1.1% among men in India. In India, the prevalence of diabetes in adults was 8.9% in 2019 and the total incidences of diabetes in adults was 77 million in 2019. Diabetes interrupts metabolism function, which increases the need for medications for the treatment of the condition. The factors that influenced the growth of metabolic disorders therapeutics market are a rise in cases of metabolic disorders such as obesity and diabetes and the presence of several approved metabolic disorders therapeutics drugs. In addition, increase research and development activities and favorable government policies are considered a positive indicator for the growth of metabolic disorders therapeutics.
The rise in sedentary jobs, busy lifestyles and changing consumer preferences are affecting the disease profile, especially non-communicable diseases such as diabetes and obesity. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of metabolic disorders. Other factors includes, increasing demand for one-time therapies for metabolic disorders and the rising prevalence of lifestyle diseases are the key factors that are expected to boost the growth of this market. Also, rising incidences of inherited metabolic diseases due to changing lifestyles are likely to propel the market growth.
Major Metabolic Disorders
The major disorders include diabetes, lysosomal disorders, hypercholesterolemia, obesity, and inherited metabolic disorders. These diseases are mostly inherited from the older generation through a faulty gene and some show immediate effects like the lysosomal disorders, while some show up later due to aging. Diabetes was estimated to be the largest segment due to the wide usage of metabolic disease therapies in anti-diabetic drugs and injections to control the blood sugar levels.